Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Natera Inc
(NQ:
NTRA
)
168.45
+0.13 (+0.08%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Natera Inc
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO
September 16, 2024
From
Natera, Inc.
Via
Business Wire
First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival
September 14, 2024
From
Natera, Inc.
Via
Business Wire
Analyst Scoreboard: 9 Ratings For Natera
September 13, 2024
Via
Benzinga
Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
September 08, 2024
From
Natera, Inc.
Via
Business Wire
Peering Into Natera's Recent Short Interest
September 06, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Natera Through Analyst Insights
August 27, 2024
Via
Benzinga
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
August 20, 2024
The recent stock market dip provided some discounts.
Via
The Motley Fool
Shopify, Palantir And Uber Are Among Top 10 Large Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
August 11, 2024
Top 10 best performing large-cap stocks last week: Shopify, Palantir, Axon, Fortinet, Trade Desk, Natera, SharkNinja, Zillow, Aspen Tech, Uber.
Via
Benzinga
Forecasting The Future: 6 Analyst Projections For Natera
August 09, 2024
Via
Benzinga
NTRA Stock Earnings: Natera Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
NTRA stock results show that Natera beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Natera Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Natera, Inc.
Via
Business Wire
$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today
August 06, 2024
Via
Benzinga
(NTRA) - Analyzing Natera's Short Interest
July 23, 2024
Via
Benzinga
Here's How Much You Would Have Made Owning Natera Stock In The Last 5 Years
July 18, 2024
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
August 08, 2024
Via
Benzinga
Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 06, 2024
From
Natera, Inc.
Via
Business Wire
Natera to Report its Second Quarter 2024 Results on August 8, 2024
July 30, 2024
From
Natera, Inc.
Via
Business Wire
New MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell Carcinoma
July 26, 2024
From
Natera, Inc.
Via
Business Wire
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,300 Today
July 04, 2024
Via
Benzinga
The 3 Best Gene Editing Stocks to Buy in July 2024
July 08, 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks.
Via
InvestorPlace
Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
July 03, 2024
From
Natera, Inc.
Via
Business Wire
Trading SMID Biotech Stocks In A Volatile Market
July 01, 2024
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a...
Via
Talk Markets
Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer
June 27, 2024
From
Natera, Inc.
Via
Business Wire
$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today
June 20, 2024
Via
Benzinga
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
June 18, 2024
Myriad Genetics Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including
Via
MarketBeat
Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients
June 17, 2024
From
Natera, Inc.
Via
Business Wire
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,400 Today
June 13, 2024
Via
Benzinga
Amazon, Natera And A Financial Stock: CNBC's 'Final Trades'
June 11, 2024
The recommendation comes after a former Amazon employee accused the Seattle-based company of selling technology to Russia.
Via
Benzinga
Breaking Down Natera: 10 Analysts Share Their Views
June 03, 2024
Via
Benzinga
Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 03, 2024
From
Natera, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.